Meeting
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
Authors
Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD
Catherine Handy Marshall , Lukasz Gondek , Elizabeth Mauer , Calvin Y. Chao , Jun Luo , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10522)
DOI
10.1200/JCO.2023.41.16_suppl.10522
Abstract #
10522
Poster Bd #
155
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis
Poster
2023 ASCO Quality Care Symposium
CHIPping in: Clonal hematopoiesis clinics in community oncology.
First Author: Michael Byrne
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen